Lixte Biotechnology Holdings Inc (LIXT)
2.89
+0.01
(+0.27%)
USD |
NASDAQ |
May 03, 16:00
2.89
0.00 (0.00%)
After-Hours: 20:00
Lixte Biotechnology Holdings Research and Development Expense (Quarterly): 0.1491M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.1491M |
| September 30, 2023 | 0.1325M |
| June 30, 2023 | 0.4275M |
| March 31, 2023 | 0.1891M |
| December 31, 2022 | 0.4536M |
| September 30, 2022 | 0.2724M |
| June 30, 2022 | 0.1648M |
| March 31, 2022 | 0.4585M |
| December 31, 2021 | 0.8037M |
| September 30, 2021 | 0.2272M |
| June 30, 2021 | 0.2624M |
| March 31, 2021 | 0.4435M |
| December 31, 2020 | 0.2116M |
| September 30, 2020 | 0.7994M |
| June 30, 2020 | 0.1179M |
| March 31, 2020 | 0.0947M |
| December 31, 2019 | 0.1219M |
| September 30, 2019 | 0.5706M |
| June 30, 2019 | 0.0801M |
| March 31, 2019 | 0.0483M |
| December 31, 2018 | -0.0295M |
| September 30, 2018 | 0.0035M |
| June 30, 2018 | 0.0411M |
| March 31, 2018 | 0.0257M |
| December 31, 2017 | 0.1038M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.2057M |
| June 30, 2017 | 0.0146M |
| March 31, 2017 | 0.1432M |
| December 31, 2016 | 0.1507M |
| September 30, 2016 | 0.336M |
| June 30, 2016 | 0.3169M |
| March 31, 2016 | 0.2645M |
| December 31, 2015 | 0.675M |
| September 30, 2015 | 0.6244M |
| June 30, 2015 | 0.287M |
| March 31, 2015 | 0.5055M |
| December 31, 2014 | 0.3104M |
| September 30, 2014 | 0.3091M |
| June 30, 2014 | 0.3357M |
| March 31, 2014 | 0.1628M |
| December 31, 2013 | 0.2449M |
| September 30, 2013 | 0.2199M |
| June 30, 2013 | 0.2488M |
| March 31, 2013 | 0.1663M |
| December 31, 2012 | 0.1277M |
| September 30, 2012 | 0.3937M |
| June 30, 2012 | 0.2173M |
| March 31, 2012 | 0.2736M |
| December 31, 2011 | 0.4848M |
| September 30, 2011 | 0.3644M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.0801M
Minimum
Jun 2019
0.8037M
Maximum
Dec 2021
0.3148M
Average
0.2272M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| iBio Inc | 1.535M |
| PAVmed Inc | 3.595M |
| PDS Biotechnology Corp | 7.466M |
| Moleculin Biotech Inc | 6.632M |
| Syros Pharmaceuticals Inc | 21.50M |